jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2014-6-2-48-54jofin-237Research ArticleОригинальные исследованияOriginal ResearchЗНАЧЕНИЕ НЕКОТОРЫХ ГЕНЕТИЧЕСКИХ ФАКТОРОВ ДЛЯ ПРОГНОЗА ЭФФЕКТИВНОСТИ ПРОТИВОВИРУСНОГО ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА СThe value of some genetic factors for prediction of chronic hepatitis C antiviral treatment effectivenessМицураВ. М.MitsuraV. M.

доцент кафедры инфекционных болезней Гомельского государственного медицинского университета, к.м.н., доцент; тел.: (+375 232)516728

mitsura_victor@tut.byГомельский государственный медицинский университет, Гомель, БеларусьРоссияGomel State Medical University, Gomel, BelarusRussian Federation201417092014624854Copyright © Мицура В.М., 20142014Мицура В.М.Mitsura V.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/237Цель

Цель: определение значения полиморфизмов гена интерлейкина 28B (ИЛ-28В) и рибонуклеазы L (РНКазы L), а также аллелей HLA DRB1*1101 и HLA-DQB1*03 для прогноза эффективности противовирусного лечения хронического гепатита С (ХГС).

Материалы и методы

Материалы и методы. Обследовано 156 стационарных пациентов с ХГС (65,4% мужчины; 62,4% с генотипом 1 вируса гепатита С – ВГС). Результаты лечения препаратами интерферона (IFN) и рибавирина (RBV) проанализированы у 74 пациентов. Методом полимеразной цепной реакции определялись единичные нуклеотидные полиморфизмы (SNP) гена ИЛ-28B 39743165T>G (rs8099917), SNP 39738787C>T (rs12979860) и гена РНКазы L (1385G>A), а также аллели HLA DRB1*1101 и HLA-DQB1*03.

Результаты

Результаты. У пациентов с генотипом 1 ВГС чаще встречаются мутантные аллели в SNP 39743165T>G (р=0,001) и 39738787C>T (р=0,0002), чем у больных с иными генотипами вируса. Ответ на терапию IFN/RBV был выше при «благоприятных» вариантах ТТ (SNP 39743165T>G) и СС (SNP 39738787C>T), при их сочетании вирусологический ответ составляет 70,6%. Различий в эффективности терапии у лиц в зависимости от вариантов полиморфизма 6552G>A (rs486907) гена РНКазы L и носительства аллелей HLA-DRB1*11 и HLA-DQB1*03 не выявлено.

Заключение

Заключение. Обследование на SNP 39738787C>T гена ИЛ-28B рекомендуется перед началом терапии IFN/RBV всем пациентам с генотипом 1 ВГС в качестве прогностического фактора ответа на лечение. SNP 1385G>A гена РНКа-зы L и носительство аллелей HLA-DRB1*11 и HLA-DQB1*03 не имеют прогностического значения при терапии ХГС.

Aim

Aim: To determine the value of gene polymorphisms of interleukin-28B (IL28B), RNase L, HLA DRB1*1101 and HLADQB1*03 alleles as predictors of antiviral treatment efficacy in patients with chronic hepatitis C (CHC).

Material and methods

Material and methods. A total of 156 in-patients with chronic hepatitis C (65.4% men, 62.4% had genotype 1 hepatitis C virus – HCV) were studied. The results of treatment with interferon (IFN) and ribavirin (RBV) were analyzed in 74 patients. Polymerase chain reaction identified single nucleotide polymorphisms (SNP) of the gene IL28B 39743165T>G (rs8099917), SNP 39738787C> T (rs12979860), RNase L gene (1385G>A), HLA DRB1*1101 and HLA-DQB1*03 alleles.

Results

Results. In patients with HCV genotype 1 mutant alleles were more common in SNP 39743165T>G (p=0.001) and 39738787C>T (p=0.0002) than in patients with other genotypes. Response to therapy IFN/RBV was higher in those with “favorable” TT variant (SNP 39743165T>G) and CC (SNP 39738787C>T), in those with their combination virologic response ffect were found according to genes IL28B and RNase L SNP variants, DRB1*1101 and HLA-DQB1*03 alleles.

Conclusion

Conclusion. Testing for SNP 39738787C>T of IL28B gene is recommended before starting therapy IFN / RBV for all patients with genotype 1 HCV as a predictor of treatment response. Testing SNP 1385G>A gene RNase L and DRB1*1101, HLA-DQB1*03 alleles has no apparent prognostic value for patients with CHC antiviral therapy.

полиморфизм гена ИЛ-28BРНКа- за LHLA-DRB1*11HLA-DQB1*03хронический гепатит СинтерферонотерапияSNPIL28BRNase LHLA-DRB1*11HLADQB1* 03chronic hepatitis Cinterferon therapyReferencesGhany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct; 54(4): 1433– 1444.Ghany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct; 54(4): 1433– 1444.McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Aug;361:580-93.McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Aug;361:580-93.EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011 Aug; 55(2): 245-64.EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011 Aug; 55(2): 245-64.Rau M, Baur K, Geier A. Host Genetic Variants in the Pathogenesis of Hepatitis C. Viruses. 2012 Dec; 4(12): 3281-3302.Rau M, Baur K, Geier A. Host Genetic Variants in the Pathogenesis of Hepatitis C. Viruses. 2012 Dec; 4(12): 3281-3302.Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011 Jan; 106(1): 38–45.Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011 Jan; 106(1): 38–45.Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology. 2011 Jan; 53(1): 336-45.Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology. 2011 Jan; 53(1): 336-45.Rauch A, Kutalik Z, Descombes P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology. 2010 Apr; 138(4): 1338-45, 1345.e1-7.Rauch A, Kutalik Z, Descombes P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology. 2010 Apr; 138(4): 1338-45, 1345.e1-7.Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep; 461(7262): 399-401.Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep; 461(7262): 399-401.Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 Oct; 41(10): 1105-9.Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 Oct; 41(10): 1105-9.Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin- 28B polymorphism improves viral kinetics and s the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul; 139(1): 120-9. e18.Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin- 28B polymorphism improves viral kinetics and s the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul; 139(1): 120-9. e18.Grebely J, Petoumenos K, Hellard M, et al. Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010 Oct; 52(4): 1216-24.Grebely J, Petoumenos K, Hellard M, et al. Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010 Oct; 52(4): 1216-24.Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct; 461(7265): 798-801.Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct; 461(7265): 798-801.Lin C-Y, Chen J-Y, Lin T-N, et al. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection PLoS One. 2011; 6(3): e18322.Lin C-Y, Chen J-Y, Lin T-N, et al. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection PLoS One. 2011; 6(3): e18322.Slev P. Host genomics and HCV personalized medicine. Ann Clin Lab Sci. 2012 Fall; 42(4): 363-9.Slev P. Host genomics and HCV personalized medicine. Ann Clin Lab Sci. 2012 Fall; 42(4): 363-9.Bisbal C, Silverman RH. Diverse functions of RNase L and implications in pathology. Biochimie 2007; 89(6-7): 789 – 798.Bisbal C, Silverman RH. Diverse functions of RNase L and implications in pathology. Biochimie 2007; 89(6-7): 789 – 798.Silverman RH. Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L during the interferon antiviral response J. Virol. 2007; 81(23): 12720 – 12729.Silverman RH. Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L during the interferon antiviral response J. Virol. 2007; 81(23): 12720 – 12729.Mihm U, Ackermann O, Welsch C, et al. Clinical relevance of the 2–5 -oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis. J Hepatol. 2009 Jan; 50(1): 49-58.Mihm U, Ackermann O, Welsch C, et al. Clinical relevance of the 2–5 -oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis. J Hepatol. 2009 Jan; 50(1): 49-58.Washenberger CL, Han JQ, Kechris KJ, et al. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res. 2007 Dec; 130(1-2): 85-95.Washenberger CL, Han JQ, Kechris KJ, et al. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res. 2007 Dec; 130(1-2): 85-95.Dai C.Y. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res. 2010 Feb; 85(2): 396-402.Dai C.Y. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res. 2010 Feb; 85(2): 396-402.Marangon AV, Moliterno RA, Sell AM, et al. Influence of HLA alleles in response to treatment with pegylated interferonalpha and ribavirin in patients with chronic hepatitis C. Int J Immunogenet. 2012 Aug; 39(4): 296-302.Marangon AV, Moliterno RA, Sell AM, et al. Influence of HLA alleles in response to treatment with pegylated interferonalpha and ribavirin in patients with chronic hepatitis C. Int J Immunogenet. 2012 Aug; 39(4): 296-302.Ali L, Mansoor A, Ahmad N, et al. Patient HLA-DRB1*and DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol. 2010 Aug; 91(Pt 8): 1931-8.Ali L, Mansoor A, Ahmad N, et al. Patient HLA-DRB1*and DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol. 2010 Aug; 91(Pt 8): 1931-8.de Rueda PM, López-Nevot MÁ, Sáenz-López P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol. 2011 Jul; 106(7): 1246-54.de Rueda PM, López-Nevot MÁ, Sáenz-López P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol. 2011 Jul; 106(7): 1246-54.Sim H, Wojcik J, Margulies M, et al. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat. 1998 Jul; 5(4): 249-53.Sim H, Wojcik J, Margulies M, et al. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat. 1998 Jul; 5(4): 249-53.Mitsura VM, Voropaev EV, Osipkina OV, et al. Laboratornaya diagnostika. Vostochnaya Evropa. 2012; 2: 86–97 (in Russian).Mitsura VM, Voropaev EV, Osipkina OV, et al. Laboratornaya diagnostika. Vostochnaya Evropa. 2012; 2: 86–97 (in Russian).Neukam K, Nattermann J, Rallón N, et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin- 28B genotype. HIV Med. 2011 Sep; 12(8): 487-93.Neukam K, Nattermann J, Rallón N, et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin- 28B genotype. HIV Med. 2011 Sep; 12(8): 487-93.

The authors declare that there are no conflicts of interest present.